Document is current

Article History

Accepted: 20 February 2021

First Online: 12 March 2021

Declarations

:

: No external funding was provided for the preparation of this article.

: EG has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, and Thermo Fisher Scientific. EG has received research grants from Pfizer, Astra Zeneca, Astellas, and Lexicon Pharmaceuticals. JMC declares consultant, advisory or speaker roles for IPSEN, Roche, Pfizer, Sanofi, Janssen, and BMS. AN declares having received honoraria for consulting from Merck, Astra Zeneca, Janssen, Incyte, Roche, Rainier Therapeutics, Clovis Oncology, Bayer, Astellas/Seattle Genetics, Ferring, and Immunomedics. AN has received grant/research support from: Merck, Ipsen, and Astra Zeneca and travel expenses from Roche, Merck, Astra Zeneca, and Janssen.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors.

: Not applicable.

: Concept, design: EG. Writing, review, and revision: All authors.